fumitremorgin derivatives (Netherlands Cancer Institute)

N/A

Report date: 2026/03/30 17:02:26

Base Information

Drug Namefumitremorgin derivatives (Netherlands Cancer Institute)
Drug Alias NameMDRI (Netherlands Cancer Institute)multidrug resistance inhibitor (Netherlands Cancer Institute)MDRI
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAnticancer multidrug resistance inhibitors
TargetsUpdating
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesNederlands Kanker Instituut
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsBreast Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A